John Holaday Ph.D., Executive Chairman
Dr. John Holaday is formerly the Managing Director and CEO of QRxPharma Ltd (QRX, ASX), a specialty pharmaceutical company headquartered in Sydney, Australia. He served as co-founder of EntreMed, Inc. (ENMD, NASDAQ) in 1992, and co-founder of Medicis Pharmaceutical Corp. (MRX, NYSE) in 1988. He also co-founded MaxCyte, Inc. and is a member of the Board of Directors of Plasmonix (Chair), Pixspan, CytImmune Sciences and Accelovance. He has raised over $500MM in private and public rounds of financing for these companies that have a collective market capitalization (or were acquired) in excess of $2 billion. Dr. Holaday served as a Captain in the US Army, and was at the Walter Reed Army Institute of Research as an officer and civilian for 21 years. Dr. Holaday obtained his BS (1966) and MS (1968) from the University of Alabama (UofA), and his PhD from the University of California San Francisco School of Medicine in 1976. He was named to the Ernst&Young’s Entrepreneur of the Year 2006 Hall of Fame, holds over 80 patents and published over 230 scientific articles, book chapters and four books.
Janette Dixon DBA, Director and Chief Executive Officer
Formerly a medical laboratory scientist, Dr. Janette Dixon has extensive commercial experience at executive management and director level in both start-up and corporate organizations in the fields of pharmaceuticals and clinical diagnostics. She previously founded and sold diagnostics companies based in Singapore and Malaysia and founded a pharmaceutical company in Singapore, managing the development of a drug for the eradication of Helicobacter pylori from the acquisition of intellectual property through to completion of Phase 2a clinical studies. Dr. Dixon has broad business development and licensing experience across Asia Pacific, North America and Europe. She previously held the role of Managing Director at Pacific Pharmaceuticals Ltd and led the restructuring of New Zealand’s largest pharmaceutical manufacturing company, outsourcing production of 130 pharmaceutical products into six countries. Dr. Dixon holds a Master’s Degree in Applied Finance and a Doctorate in Business and Administration wherein her research focused on the strategic management of biotech commercialization.
Stephen Trevisan, Director
Mr. Trevisan is an entrepreneur who has founded four companies, including Accelovance, Inc., a niche Contract Research Organization (CRO) focused primarily in oncology, vaccines, and general medicine, where he currently serves as President and CEO. Prior to Accelovance, Mr. Trevisan founded TherImmune Research Corporation, a CRO specializing in preclinical and early stage clinical drug development services for the pharmaceutical, biotechnology, and government markets. He also founded CommSys Corporation, a provider of outsourced billing services to the telecommunications industry. In 1987, Mr. Trevisan co-founded his first company, National Clinical Research Centers (NCRC), a CRO specializing in Phase II-IV clinical studies. NCRC deployed a unique method for running clinical trials which was successful in reducing the timeframe in conducting multi-center trials in broad-based indications. Each of Mr. Trevisan's prior companies maintained year-over-year growth and were ultimately acquired by public companies.
Robert Teoh, MBBS MD FRCP, Director
Robert Teoh has over 25 years’ experience in the biopharmaceutical and contract research industry in Asia, Switzerland and the USA. Robert was the founder and managing director of three pan-Asian CROs which he sold as profitable and growing concerns. Robert started Quintiles in East Asia and his earlier industry experience included positions in Sandoz (now Novartis) in Hong Kong & Switzerland, and Tanox Inc in the USA. He sat on the boards of CombinatoRx Singapore, and the Institute of Molecular & Cell Biology, Singapore and on advisory committees of Singapore's Economic Development Board, and National Science & Technology Board. Robert qualified in medicine from the University of Newcastle upon Tyne, England and trained in neurology in London at the National Hospital for Nervous Diseases, Royal Postgraduate Medical School, Hammersmith Hospital, and Guys Hospital. Following a UK Medical Research Council fellowship, he held faculty positions at Johns Hopkins University, Baltimore, and a tenured post at the Chinese University of Hong Kong. He has published over 55 papers in peer reviewed journals and three chapters in books.